Lab Technique
The Researcher's Guide to Reconstitution Ratios and Bacteriostatic Calculations
Diluent selection, concentration maths and handling technique for turning a lyophilized peptide cake into an accurate, stable working solution.
Tissue Repair · Lyophilized Powder
CAS: 137525-51-0 | Sequence: Pentadecapeptide | Purity: ≥99.2%
$49.99 / vial
In Stock - Ships Within 24 Hours
SKU PT-BPC157-5 · HPLC + MS tested every batch · Insulated cold-pack shipping
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid chain (GEPPPGKPADDAGLV, 1419.53 g/mol) — corresponding to a partial sequence of a protective protein isolated from human gastric juice. It is one of the most widely studied peptides in preclinical tissue-repair research, with published work spanning tendon, ligament, muscle, bone and gastrointestinal models.
Unusually for a peptide, BPC-157 is reported to be stable in gastric juice, which has made it a frequent subject of route-of-administration comparisons in animal studies. Mechanistic research centres on angiogenesis through VEGFR2 signalling, fibroblast migration via the FAK–paxillin pathway, growth hormone receptor expression in tendon cells, and modulation of the nitric oxide system.
Each vial contains 5 mg of lyophilized BPC-157 at ≥99.2% HPLC purity, identity-confirmed by mass spectrometry and supplied with a batch-specific third-party Certificate of Analysis.
Each production lot is independently tested for identity, purity and content. Select a batch to view its analytical results — your vial label lists the batch number.
| Test | Method | Result | Status |
|---|
Technical reference data and a summary of published preclinical literature, provided for educational purposes.
| Name | BPC-157 (Body Protection Compound-157) |
|---|---|
| Synonyms | PL 14736, PL-10, Bepecin |
| CAS Number | 137525-51-0 |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.53 g/mol |
| Sequence (3-letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Sequence (1-letter) | GEPPPGKPADDAGLV |
| Structure Class | Synthetic linear pentadecapeptide (15 amino acids), partial sequence of human gastric juice protein BPC |
| Form | White lyophilized powder |
| Purity | ≥99.2% (RP-HPLC); identity confirmed by ESI-MS |
| Content per Vial | 5 mg net peptide |
| Solubility | Soluble in water, bacteriostatic water and 0.9% saline |
| Storage Conditions | Lyophilized: −20 °C, desiccated and protected from light. Reconstituted: 2–8 °C, use within 28 days. |
Rodent and endothelial cell studies report that BPC-157 increases expression of vascular endothelial growth factor receptor 2 (VEGFR2) and activates the VEGFR2–Akt–eNOS signalling axis, which is associated with new blood-vessel formation in ischemic tissue models.
In cultured rat tendon fibroblasts, BPC-157 has been associated with increased cell survival under oxidative stress, enhanced migration and spreading via the FAK–paxillin pathway, and dose-dependent up-regulation of growth hormone receptor expression. Rat Achilles tendon transection models reported improved biomechanical and histological healing scores.
BPC-157 was first characterized from gastric juice, and much of the early literature examines its stability in gastric conditions and its effects in rodent models of mucosal lesions, including NSAID- and alcohol-induced damage and experimental fistulas.
Several studies describe modulation of the nitric oxide (NO) system, with effects that differ depending on whether NOS is pharmacologically inhibited or stimulated in the model — a frequent subject of mechanistic investigation.
Rat quadriceps transection and muscle-crush models reported improved functional, macroscopic and histological recovery scores, and a rabbit segmental bone-defect study reported enhanced osteogenesis relative to untreated controls.
The majority of published work comes from a small number of research groups and relies on rodent models. Independent replication and controlled human data remain limited, which researchers should weigh when designing studies.
Representative literature: Chang C-H et al., J Appl Physiol 2011; Hsieh M-J et al., J Mol Med 2017; Seiwerth S et al., Curr Pharm Des 2018; Sikiric P et al., Curr Neuropharmacol 2016; Sebecic B et al., Bone 1999; Staresinic M et al., J Orthop Res 2006.
| Diluent Added | Concentration | Per 0.1 mL Aliquot |
|---|---|---|
| 1.0 mL | 5.0 mg/mL | 500 µg |
| 2.0 mL | 2.5 mg/mL | 250 µg |
| 2.5 mL | 2.0 mg/mL | 200 µg |
| 3.0 mL | 1.67 mg/mL | 167 µg |
| 5.0 mL | 1.0 mg/mL | 100 µg |
Allow the vial to reach room temperature. Introduce sterile or bacteriostatic water slowly down the inner glass wall — do not inject directly onto the powder cake. Swirl gently until fully dissolved; do not shake or vortex, as this can promote aggregation.
| State | Condition | Typical Stability |
|---|---|---|
| Lyophilized | −20 °C, desiccated | 24+ months |
| Lyophilized | 2–8 °C | Up to 12 months |
| Lyophilized | Room temp (≤25 °C) | Several weeks (transit) |
| Reconstituted | 2–8 °C | Up to 28 days |
| Reconstituted | −20 °C aliquots | Avoid repeated freeze–thaw |
Lab Technique
Diluent selection, concentration maths and handling technique for turning a lyophilized peptide cake into an accurate, stable working solution.
Quality & Analytics
What a chromatogram, a purity percentage and a mass spectrum actually tell you — and the red flags that suggest a Certificate of Analysis deserves a closer look.
Research Review
Two of the most studied tissue-repair peptides work through very different mechanisms. A side-by-side look at pathways, model systems and study-design pitfalls.
Complementary research compounds and lab supplies.